Profile data is unavailable for this security.
About the company
Flerie AB, formerly InDex Pharmaceuticals Holding AB, is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company is an active long-term global biotech and pharmaceutical investor that managing a portfolio of companies in Europe, Israel, and the US. Flerie invests in companies across the entire value chain, providing exposure to opportunities across three segments: Product Development, Commercial Growth, and Limited Partnerships. The Product Development segment consists of early-stage biotech and pharma companies in product development. The Commercial Growth segment consists of companies that are already selling products or services and showcasing proof-of-concept with high growth and some that have already reached profitability. The Limited Partnerships segment provides benefits for the other two segments, including co-investment opportunities, and derisks Flerie’s investment portfolio.
- Revenue in SEK (TTM)100.00k
- Net income in SEK-269.52m
- Incorporated2016
- Employees2.00
- LocationFlerie ABSkeppsbron 16STOCKHOLM 111 30SwedenSWE
- Phone+46 812203850
- Fax+46 850884739
- Websitehttps://www.flerie.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PharmaSGP Holding SE | 1.27bn | 211.02m | 3.42bn | 93.00 | 16.20 | 9.05 | 10.70 | 2.69 | 1.52 | 1.52 | 9.15 | 2.72 | 0.8223 | 1.04 | 8.57 | 1,233,225.00 | 13.64 | 13.70 | 18.34 | 19.98 | 90.91 | 90.20 | 16.59 | 17.56 | 1.54 | 14.98 | 0.6823 | -- | 17.80 | 10.78 | 37.17 | 2.16 | 25.88 | -- |
| Adimmune Corp | 552.36m | -202.71m | 3.47bn | 564.00 | -- | 2.03 | -- | 6.29 | -1.44 | -1.44 | 3.93 | 11.92 | 0.1848 | 1.25 | 4.04 | -- | -8.27 | 0.6867 | -10.19 | 0.7739 | 27.82 | 30.11 | -44.75 | 3.04 | 1.99 | -24.75 | 0.3284 | 32.80 | -20.72 | 16.77 | -319.91 | -- | 38.05 | -- |
| Seikagaku Corp | 2.56bn | 154.06m | 3.49bn | 988.00 | 21.77 | 0.641 | 12.58 | 1.36 | 40.32 | 40.32 | 670.36 | 1,369.69 | 0.4558 | 2.01 | 4.65 | 37,018,220.00 | 2.74 | 0.4261 | 2.96 | 0.4678 | 47.46 | 54.18 | 6.01 | 0.9814 | 5.04 | -- | 0.0052 | 465.78 | 8.24 | 4.99 | -2.24 | -0.5224 | 30.28 | 0.00 |
| Flerie AB | 100.00k | -269.52m | 3.51bn | 2.00 | -- | 0.8243 | -- | 35,129.88 | -22.07 | -22.07 | 0.0019 | 54.59 | 0.00004 | -- | -- | 14,285.71 | -11.53 | -37.64 | -11.69 | -41.14 | -92,017.00 | -450.51 | -269,618.00 | -454.62 | -- | -2.58 | 0.0002 | -- | -- | 277.02 | 5.05 | -- | -- | -- |
| Niox Group PLC | 535.58m | 151.06m | 3.52bn | 85.00 | 26.42 | 3.34 | 16.75 | 6.57 | 0.0244 | 0.0259 | 0.0864 | 0.1929 | 0.4255 | 2.86 | 8.76 | 458,823.50 | 12.00 | -2.41 | 12.88 | -2.90 | 71.79 | 70.87 | 28.21 | -11.46 | 5.56 | -- | 0.0109 | -- | 17.57 | -5.29 | -32.62 | -- | -5.59 | -- |
| SCI Pharmtech Inc | 417.43m | 46.17m | 3.57bn | 241.00 | 79.05 | 2.12 | 32.41 | 8.55 | 1.13 | 1.13 | 12.70 | 42.26 | 0.2044 | 1.61 | 3.83 | -- | 2.26 | 6.90 | 2.54 | 8.26 | 27.75 | 38.18 | 11.06 | 19.85 | 1.78 | 802.61 | 0.1826 | 42.38 | 33.83 | -9.10 | -4.55 | -8.00 | 44.67 | -16.35 |
| Formosa Laboratories Inc | 1.56bn | 85.34m | 3.61bn | 480.00 | 42.62 | 1.44 | 18.03 | 2.31 | 2.11 | 2.11 | 38.90 | 62.49 | 0.3479 | 1.49 | 4.42 | -- | 0.7067 | 2.68 | 0.9689 | 3.61 | 44.30 | 35.40 | 2.03 | 8.75 | 1.18 | 0.8922 | 0.3155 | 27.38 | 15.80 | 10.16 | -69.16 | -6.52 | -11.60 | 32.22 |
| Holder | Shares | % Held |
|---|---|---|
| Fj�rde AP-fondenas of 30 Jun 2024 | 5.46m | 7.00% |
| Atlant Fonder ABas of 30 Aug 2024 | 1.07m | 1.37% |
| SEB Investment Management ABas of 30 Sep 2024 | 106.72k | 0.14% |
| Ponderus Invest ABas of 31 Dec 2023 | 62.00k | 0.08% |
| FCG Fonder ABas of 30 Sep 2024 | 30.67k | 0.04% |
| Universal-Investment-Gesellschaft mbH (Invt Mgmt)as of 31 Jul 2024 | 0.00 | 0.00% |
